Related Experiment Video

Updated: Jun 5, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

The NK-1 receptor: a new target in cancer therapy

Miguel Muñoz1, Marisa Rosso, Rafael Coveñas

  • 1Research Laboratory on Neuropeptides, Virgen del Rocío University Hospital, Sevilla, Spain. mmunoz@cica.es

Current Drug Targets
|January 14, 2011
PubMed

Insights

Substance P (SP) binding to neurokinin-1 (NK-1) receptors promotes cancer growth. NK-1 receptor antagonists inhibit this growth by inducing cancer cell death, offering a promising cancer treatment strategy.

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • Substance P (SP) is a peptide neurotransmitter found in the central and peripheral nervous systems.
  • SP binds to neurokinin-1 (NK-1) receptors, influencing tumor cell proliferation, angiogenesis, and metastasis.
  • NK-1 receptors are frequently overexpressed in various human tumors.

Purpose of the Study:

  • To investigate the role of the SP/NK-1 receptor system in cancer development.
  • To evaluate the potential of NK-1 receptor antagonists as anticancer agents.

Main Methods:

  • The study reviews existing data on the SP/NK-1 receptor interaction in cancer.
  • Analysis of the mechanisms by which SP and NK-1 receptor antagonists affect tumor cells, including apoptosis induction.

Main Results:

  • SP binding to NK-1 receptors promotes tumor cell proliferation, angiogenesis, and migration.
  • NK-1 receptor antagonists inhibit these processes and induce apoptosis in cancer cells.
  • SP acts as a mitogen for NK-1 receptor-expressing tumor cells.

Conclusions:

  • The SP/NK-1 receptor system is implicated in cancer development and progression.
  • NK-1 receptor antagonists demonstrate broad-spectrum antitumor activity.
  • Targeting the NK-1 receptor represents a promising therapeutic strategy for human cancers.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...